Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer

Sheena Bhalla, Farjana Fattah, Chul Ahn, Jessica N. Williams, Alyssa Macchiaroli, Jonathan Padro, Meredith Pogue, Jonathan E. Dowell, William C. Putnam, Nigel McCracken, David Micklem, Rolf A. Brekken, David E. Gerber